1626 related articles for article (PubMed ID: 27764810)
1. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
[TBL] [Abstract][Full Text] [Related]
2. EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression.
Satelli A; Batth I; Brownlee Z; Mitra A; Zhou S; Noh H; Rojas CR; Li H; Meng QH; Li S
Oncotarget; 2017 Jul; 8(30):49329-49337. PubMed ID: 28521303
[TBL] [Abstract][Full Text] [Related]
3. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
[TBL] [Abstract][Full Text] [Related]
4. Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate with the clinical stages and cancer metastasis in hepatocellular carcinoma patients.
Chen J; Cao SW; Cai Z; Zheng L; Wang Q
Cancer Biomark; 2017 Dec; 20(4):487-498. PubMed ID: 28869439
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
[TBL] [Abstract][Full Text] [Related]
6. EMT-independent detection of circulating tumor cells in human blood samples and pre-clinical mouse models of metastasis.
Kitz J; Goodale D; Postenka C; Lowes LE; Allan AL
Clin Exp Metastasis; 2021 Feb; 38(1):97-108. PubMed ID: 33415568
[TBL] [Abstract][Full Text] [Related]
7. Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer.
Chen J; Cao S; Situ B; Zhong J; Hu Y; Li S; Huang J; Xu J; Wu S; Lin J; Zhao Q; Cai Z; Zheng L; Wang Q
J Exp Clin Cancer Res; 2018 Jun; 37(1):127. PubMed ID: 29954422
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
[TBL] [Abstract][Full Text] [Related]
9. Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer.
Zhao R; Cai Z; Li S; Cheng Y; Gao H; Liu F; Wu S; Liu S; Dong Y; Zheng L; Zhang W; Wu X; Yao X
Oncotarget; 2017 Feb; 8(6):9293-9302. PubMed ID: 28030836
[TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor Cells and Implications of the Epithelial-to-Mesenchymal Transition.
Lowes LE; Allan AL
Adv Clin Chem; 2018; 83():121-181. PubMed ID: 29304900
[TBL] [Abstract][Full Text] [Related]
11. Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients.
Togo S; Katagiri N; Namba Y; Tulafu M; Nagahama K; Kadoya K; Takamochi K; Oh S; Suzuki K; Sakurai F; Mizuguchi H; Urata Y; Takahashi K
Oncotarget; 2017 May; 8(21):34884-34895. PubMed ID: 28432274
[TBL] [Abstract][Full Text] [Related]
12. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
13. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
[TBL] [Abstract][Full Text] [Related]
15. Current and future role of circulating tumor cells in patients with epithelial ovarian cancer.
Van Berckelaer C; Brouwers AJ; Peeters DJ; Tjalma W; Trinh XB; van Dam PA
Eur J Surg Oncol; 2016 Dec; 42(12):1772-1779. PubMed ID: 27265041
[TBL] [Abstract][Full Text] [Related]
16. Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System.
Xu L; Mao X; Imrali A; Syed F; Mutsvangwa K; Berney D; Cathcart P; Hines J; Shamash J; Lu YJ
PLoS One; 2015; 10(9):e0138032. PubMed ID: 26397728
[TBL] [Abstract][Full Text] [Related]
17. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer.
Li S; Chen Q; Li H; Wu Y; Feng J; Yan Y
Clin Transl Oncol; 2017 Sep; 19(9):1147-1153. PubMed ID: 28374320
[TBL] [Abstract][Full Text] [Related]
19. Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics.
Chen W; Allen SG; Reka AK; Qian W; Han S; Zhao J; Bao L; Keshamouni VG; Merajver SD; Fu J
BMC Cancer; 2016 Aug; 16():614. PubMed ID: 27501846
[TBL] [Abstract][Full Text] [Related]
20. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]